These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of amfonelic acid, alpha-methyltyrosine, Ro 4-1284 and haloperidol pretreatment on the depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Fuller RW; Hemrick-Luecke SK Res Commun Chem Pathol Pharmacol; 1985 Apr; 48(1):17-25. PubMed ID: 3873102 [TBL] [Abstract][Full Text] [Related]
23. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety. Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166 [TBL] [Abstract][Full Text] [Related]
24. Behavioral and biochemical changes following acute administration of MPTP and MPP+. Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017 [TBL] [Abstract][Full Text] [Related]
25. Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease. Sershen H; Hashim A; Lajtha A Pharmacol Biochem Behav; 1987 Oct; 28(2):299-303. PubMed ID: 3500479 [TBL] [Abstract][Full Text] [Related]
26. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135 [TBL] [Abstract][Full Text] [Related]
27. Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent. Zimmerman DM; Cantrell BE; Reel JK; Hemrick-Luecke SK; Fuller RW J Med Chem; 1986 Aug; 29(8):1517-20. PubMed ID: 3488406 [TBL] [Abstract][Full Text] [Related]
28. Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. Plangár I; Zádori D; Szalárdy L; Vécsei L; Klivényi P Ideggyogy Sz; 2013 Nov; 66(11-12):407-14. PubMed ID: 24555241 [TBL] [Abstract][Full Text] [Related]
29. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on striatal dopamine receptors in C57BL/6 mice. Bhargava HN; Perlow MJ Toxicol Lett; 1988 Mar; 40(3):219-24. PubMed ID: 3258448 [TBL] [Abstract][Full Text] [Related]
30. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Fuller RW; Hemrick-Luecke SK Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779 [TBL] [Abstract][Full Text] [Related]
31. Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) in mouse brain. Pileblad E; Nissbrandt H; Carlsson A J Neural Transm; 1984; 60(3-4):199-203. PubMed ID: 6084705 [TBL] [Abstract][Full Text] [Related]
32. Characterization of hepatic microsomal metabolism as an in vivo detoxication pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Chiba K; Kubota E; Miyakawa T; Kato Y; Ishizaki T J Pharmacol Exp Ther; 1988 Sep; 246(3):1108-15. PubMed ID: 3262153 [TBL] [Abstract][Full Text] [Related]
33. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Sonsalla PK; Heikkila RE Eur J Pharmacol; 1986 Oct; 129(3):339-45. PubMed ID: 3490988 [TBL] [Abstract][Full Text] [Related]
34. Partially protective effect of amantadine in the MPTP model of Parkinson's disease. Rojas P; Altagracia M; Kravsov J; Rios C Proc West Pharmacol Soc; 1992; 35():33-5. PubMed ID: 1502234 [No Abstract] [Full Text] [Related]
35. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758 [TBL] [Abstract][Full Text] [Related]
36. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Brain Res; 1987 Jul; 415(2):293-9. PubMed ID: 3496938 [TBL] [Abstract][Full Text] [Related]
37. 4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity. Irwin I; Langston JW; DeLanney LE Life Sci; 1987 Feb; 40(8):731-40. PubMed ID: 3492652 [TBL] [Abstract][Full Text] [Related]
38. Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Boyce S; Kelly E; Reavill C; Jenner P; Marsden CD Biochem Pharmacol; 1984 Jun; 33(11):1747-52. PubMed ID: 6610420 [TBL] [Abstract][Full Text] [Related]
39. Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Heikkila RE Eur J Pharmacol; 1985 Oct; 117(1):131-3. PubMed ID: 3878793 [TBL] [Abstract][Full Text] [Related]
40. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Perry TL; Yong VW; Clavier RM; Jones K; Wright JM; Foulks JG; Wall RA Neurosci Lett; 1985 Sep; 60(2):109-14. PubMed ID: 3877260 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]